Jacinto Solivellas de Oleza, a strategic investment consultant at Olesis Management, supports leukemia care and research. Solivellas founded the Alexcar Leukemia Foundation, a non-profit dedicated to patients and families living with leukemia.
Last month, scientists at Memorial Sloan-Kettering Cancer Center published new research in leukemia studies related to B cell acute lymphoblastic leukemia, also called B-ALL. Research suggests that new gene therapy may provide a viable treatment option in patients for whom chemotherapy was not effective.
In scientific trials, patients were treated with genetically modified T cells that attacked their cancerous B cells. Patients also underwent stem cell transplants. In a promising outcome, the leukemia of all five patients went into remission.
Scientists are calling these results dramatic and exciting. Though the research is experimental, it could provide breakthroughs in treatment for a type of leukemia that has historically been life-threatening and lethal. The research was sponsored by the National Institutes of Health (NIH).